Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news releases dated December 22, 2017, it has entered into a definitive agreement (the â€œDefinitive Agreementâ€) to acquire (the â€œAcquisitionâ€) Green Tree Therapeutics Corporation (â€œGTTâ€, â€œGreen Treeâ€ or â€œGT Therapeutics Corporationâ€).
GTTâ€™s brands are currently sold in a wide variety of brick and mortar locations across North America, including wholesale channels. The Green Tree acquisition will bring Abattis 10 unique branded SKUs and a series of marketing, licensing, and technology rights. Upon closing of the Acquisition, products within the Green Tree brand will made available through Abattisâ€™s wholly-owned subsidiary Vergence Naturals Ltd. (â€œVergenceâ€).
â€œAbattis has always seen Green Tree as a perfect fit to merge with existing products within our marketing wing in Vergence,â€ stated Rob Abenante, President and CEO of Abattis. â€œAcquiring GTT will complement our retail offerings through Vergence and provide a solid entry point into the vaporizers market.â€
Click here to read the original article.